Nucleoside Therapy for HIV Infection — Some Answers, Many Questions

Publisher Website
Google Scholar
Abstract
The dideoxynucleoside analogues are a family of antiretroviral agents whose mechanism of action is inhibition of the human immunodeficiency virus (HIV) reverse transcriptase.1 Zidovudine, the first member of this family to be approved for the treatment of HIV disease, has recently been joined in clinical practice by its cousins, didanosine and dideoxycytidine, with still other nucleoside analogues moving through the stages of preclinical and clinical development. Because of the expanding number of therapeutic choices, the optimal use of these nucleosides needs to be determined. Issues of antiviral potency, drug toxicity, the emergence of viral resistance, and the immune status of . . .